From Purdue's Ashes: Knoa Pharma Rises with a Mandate to Heal

STAMFORD, CT – May 01, 2026 – In a move of unprecedented legal and corporate restructuring, the company at the heart of the American opioid epidemic, Purdue Pharma L.P., has permanently ceased to exist. In its place, a new entity, Knoa Pharma LLC, begins operations today, born from the crucible of a multi-billion-dollar bankruptcy settlement and tasked with an extraordinary mission: to help abate the very crisis its predecessor is blamed for creating.

Knoa Pharma launches not as a typical pharmaceutical corporation, but as a public-benefit company wholly owned by a new non-profit, the Knoa Foundation. This unique structure is the cornerstone of a complex, court-approved plan years in the making, designed to redirect the profits from Purdue's former assets, including the continued sale of opioid analgesics, toward funding national opioid abatement efforts. The company begins its journey under intense scrutiny, facing the monumental challenge of earning public trust while operating in the long shadow of Purdue's devastating legacy.

A New Model of Corporate Atonement

The entire framework of Knoa Pharma is designed to be an inversion of Purdue's. Where Purdue was privately owned and relentlessly pursued profit, Knoa is owned by the 501(c)(4) Knoa Foundation, legally binding it to a public health purpose. The value generated by the company's operations is earmarked to support communities ravaged by the opioid crisis.

This includes a core commitment to provide overdose reversal agents and medications for opioid use disorder (OUD) on a not-for-profit basis, making them available at or below the cost of production. The goal is to dramatically increase access to these life-saving treatments for first responders, healthcare providers, and public health programs nationwide.

“Knoa Pharma’s unique model ensures that the company’s resources directly support public health,” said Dr. Paul Rothman, the newly appointed Chair of the Knoa Foundation Board of Trustees and former CEO of Johns Hopkins University School of Medicine. “Through not‑for‑profit access to overdose reversal medicines and treatments for opioid use disorder, Knoa Pharma is committed to providing care and saving lives in communities most affected by the opioid crisis.”

This structure is the result of a landmark $7.4 billion settlement with the Department of Justice, numerous states, territories, and personal injury victims. The Sackler family, former owners of Purdue, contributed billions to this fund and are now permanently barred from the opioid business in the United States, with no role or stake in the new company.

A Framework for Accountability

To prevent a repeat of past failures, Knoa Pharma has been established with a multi-layered governance system intended to ensure transparency and accountability. The company is overseen by two entirely new, independent boards whose members have no prior association with Purdue Pharma.

The Knoa Foundation Board of Trustees features prominent figures from public health and policy, including Dr. Rothman; Rahul Gupta, the first physician to lead the White House Office of National Drug Control Policy; and David Saltzman, co-founder of New York’s largest poverty-fighting philanthropy, The Robin Hood Foundation.

Separately, the Knoa Pharma Board of Directors is composed of experts in pharmaceuticals, corporate governance, and finance, chaired by Dr. Norbert Riedel, a veteran pharmaceutical executive. This board is tasked with the day-to-day operational oversight of the company.

“Knoa Pharma launches with the scientific expertise, governance, and operational discipline needed to deliver essential medicines safely and responsibly,” Dr. Riedel stated. “Our focus now is on building a sustainable and accountable company that can meet critical patient needs and support the broader public health purpose entrusted to us.”

Adding another layer of oversight, former Montana Governor Steve Bullock will serve as an independent monitor. With unfettered access to company records and facilities, Bullock is responsible for ensuring Knoa Pharma adheres to a strict operating injunction designed to prevent the illegal diversion of its products and prohibit the kind of deceptive marketing practices that made Purdue infamous.

From Profit to Public Health

While Knoa Pharma will continue to manufacture and sell Purdue’s existing portfolio of medicines, including opioid analgesics for patients with documented medical needs, it will do so under the strict injunction that expressly forbids the promotion of these products. This is a critical distinction that aims to balance patient access with public safety.

The company's roughly 450 employees are transferring from Purdue to the new entity, which will remain headquartered in Stamford. Marc Kesselman, who served as Purdue's Chief Legal Officer and was instrumental in shaping the new structure, has been appointed as interim CEO while a search for a permanent leader is conducted.

The launch of Knoa Pharma has been met with a mixture of cautious optimism and deep-seated skepticism. Public health officials, including some state attorneys general who fought Purdue for years, have acknowledged the settlement as a pivotal step. They see the potential for billions of dollars to finally flow to addiction treatment and prevention programs.

However, for many victims and their families, the arrangement feels like incomplete justice. While the Sackler family has paid a steep financial price, their settlement granted them broad immunity from future civil lawsuits related to the opioid crisis. Furthermore, reports have indicated that many individual claims for compensation from the settlement fund have been rejected, and the payments for those approved are seen by some as insultingly small given the scale of their loss. The new enterprise represents an unprecedented experiment in corporate rehabilitation, but its success will ultimately be judged by its tangible impact on reversing the tide of an epidemic that has claimed over a million American lives.